## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

# 208551Orig1s000

## **STATISTICAL REVIEW(S)**



U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Translational Sciences Office of Biostatistics

### STATISTICAL REVIEW AND EVALUATION MEMO

#### **Clinical Studies**

NDA #:	NDA 208551
Supplement #:	S000
Drug Name:	Triferic ® (Ferric Pyrophosphate Citrate)
Indication(s):	For the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).
Applicant:	Rockwell Medical, Inc.
<b>Receipt Date:</b>	June 25, 2015
<b>PDUFA Date:</b>	April 25, 2016
<b>Completion Date:</b>	
<b>Review Priority:</b>	Standard
<b>Biometrics Division:</b>	Division of Biometrics V
Statistical Reviewer:	Yuan-Li Shen
<b>Concurring Reviewers:</b>	Rajeshwari Sridhara
Medical Division:	Oncology and Hematology Product
<b>Clinical Team:</b>	Min Lu, Medical Reviewer
	Kathy Robie-Suh, Team Leader
Project Manager:	Scott Kimberly

#### **Keywords:**

http://intranetapps fda.gov/scripts/ob apps/ob/eWork/uploads/eWork/2009/Keywords-in-DFS.htm

#### Memo to be filed:

The original Triferic ® (Ferric Pyrophosphate Citrate) solution is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). This submission is to seek approval of the new powder form which contains the same iron concentration in the final hemodialysate provided by Triferic Solution. Triferic powder package is intended to be used in dialysis center to prepare master batches of dialysate for use in patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). Reference is made to NDA206317 for statistical review of the efficacy aspect of Triferic based on the older Triferic soluation. Since there is no additional clinical data submitted, no statistical review was conducted for this submission. This statistical review memo documents the fact that no statistical review is necessary.

### This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

-----

/s/

YUAN L SHEN 04/22/2016

RAJESHWARI SRIDHARA 04/25/2016 \_\_\_\_\_